The frequency of Tim-3 on circulating Tfh cells was increased in type 2 diabetes mellitus patients

Abstract

Type 2 diabetes mellitus (T2DM) is a chronic, low-grade inflammation disease. T follicular helper (Tfh) cells and T cell immunoglobulin and mucin domain 3 (Tim-3) are implicated in many immune diseases. This study aims to explore whether Tim-3 expression on Tfh cells is associated with T2DM progression. White blood cells (WBCs) were harvested from 30 patients with T2DM and 20 healthy donors. The abundance of circulating Tfh cells (cTfh) and the frequency of Tim-3 were analyzed by flow cytometry. Levels of fasting plasma glucose (FPG), insulin, hemoglobin A1C (HbA1C), and fasting plasma C-peptide were measured. Body mass index (BMI) and diabetes duration were also recorded. Patients with T2DM had higher numbers of cTfh cells. In addition, cTfh cells showed a negative correlation with HbA1C and diabetes duration, a positive correlation with fasting plasma C-peptide. The frequency of Tim-3 on cTfh cells was higher among T2DM patients compared with healthy donors. The in vitro experiment showed that high glucose levels increased the abundance cTfh cells but had no effect on Tim-3 expression. Our results suggest that cTfh cells and associated Tim-3 frequency may contribute to the progression of T2DM, and high glucose levels may influence cTfh cells directly.

Keywords

T2DM Tfh Tim-3

Introduction

There are around 425 million adults with diabetes worldwide, accounting for about 5.6% of the global population.¹ Of those, 90% is have type 2 diabetes mellitus (T2DM).² T2DM is characterized by “relative insulin deficiency,” with two key factors, insulin resistance and β cell dysfunction.³ Recent research has focused on the immunological mechanisms underlying T2DM. It is widely believed that chronic low-grade inflammation is related to insulin resistance in T2DM.⁴ However, most previous research has focused on the role of adipose cells,^5,6 macrophages,⁷ regulatory T cells (Treg),⁸ natural killer cells (NK),⁹ Th cells (Th1, Th2, Th17),¹⁰ and corresponding pro-inflammatory factors such as TNF-α,¹¹ IL-1β,¹² IL-6,¹³ and IFN-γ.¹⁴ Importantly, the function of T follicular helper cells (Tfh) and their potential role in T2DM remains unexplored.

Tfh cells are a subset of T cells that promote B cell maturity and are identified by surface expression of CD4⁺ and CXCR5^high.¹⁵ High expression of transcription factor B cell lymphoma 6 (BCL-6), interleukin-21 (IL-21) and the IL-6 receptor (IL-6R) are also observed on Tfh cells.¹⁶ Due to the relationship between Tfh cells and humoral immunity, there is a known link between increased abundance of Tfh cells and many autoimmune diseases, including type 1 diabetes mellitus (T1DM),¹⁷ myasthenia gravis (MG),¹⁸ systemic lupus erythematosus (SLE),¹⁹ and Graves’ disease.²⁰ However, the study of Tfh cells in T2DM is rare, and few studies have reported high numbers of Tfh cells patients with T2DM²¹ and diabetic nephropathy (DN),²² which is a major complication of diabetes. Accordingly, more in-depth and detailed research is needed to explore the correlation between Tfh cells and T2DM.

Tim-3 (T cell immunoglobulin and mucin domain 3) was initially identified as an immunosuppressive molecule,²³ and later found to be expressed in dendritic cells,²⁴ NK cells,²⁵ macrophages/monocytes,²⁶ activated T helper 17 cells²⁷ and cytotoxic T cells (CTL).²⁸ It has been reported that Tim-3 mediates immune tolerance in anti-tumor immunity,²⁹ and the anti-tumor efficacy of Tim-3 inhibition has been demonstrated in mice.³⁰ Recent research showed a potential link between Tim-3 and T2DM characterized by elevation of peripheral blood galectin-9 (the ligand of Tim-3) in patients with T2DM.³¹ Tim-3 upregulation has also been observed in renal tissue in DN.³² However, further study of the correlation between Tim-3 expression on Tfh cells and T2DM is required.

We analyzed the abundance of cTfh cells and the frequency of Tim-3 on cTfh cells in patients with T2DM and healthy donors, and further explored the potential relationship with T2DM pathology. To further validate the authenticity of our results, we designed an in vitro experiment with high and low glucose stimulation of lymphocytes from healthy donors.

Methods

Blood samples data

30 T2DM patient blood samples from the Endocrinology Department of Qilu Hospital and 20 healthy donor blood samples from the clinical lab of Qilu Hospital were obtained (the sample size was not selected by any power calculation which is the limitation of our study). White blood cells (WBCs) were collected using red blood cell lysis buffer (Solarbio, USA). All samples were negative for specific virus infection or other diseases which could affect the immune system. Our study was approved by the medical ethics committee of Shandong University. Informed consent was obtained from each patient. Baseline characteristics are shown in Table 1.

Table 1.

Clinical characteristics of blood samples.

Characteristics	T2DM patients (n = 30)	Healthy donors (n = 20)
Male, Female	18, 12	11, 9
Age, years (range)	60 (42–76)	56 (39–67)
Fasting plasma glucose (mmol/L)	10.27 ± 0.5750	4.21 ± 0.4023
Fasting plasma C-peptide (ng/ml)	1.10 ± 0.1096	3.14 ± 0.3081
BMI (kg/m²)	25.90 ± 0.9927	23.02 ± 0.3946
HbA1C (%)	7.82 ± 0.4091	5.254 ± 0.982
Insulin (uIU/mL)	12.16 ± 1.6490	10.82 ± 5.09
Diabetes duration (years)	10.80 ± 1.2300	–

Flow cytometry (FCM) detection

Isolated WBCs were stained with corresponding antibodies (anti-CD4 (ebioscience, USA), anti-Tim-3 (ebioscience, USA), anti-CXCR5 (ebioscience, USA). Cells were incubated with antibodies for 30 min at room temperature and analyzed by FACS Aria II (Figures 1 –3).

Figure 1.

The circulating Tfh cells in T2DM patients and controls. WBCs were isolated from patients (n = 30) and controls (n = 20): (a) the scatter diagram for Tfh cells marked with CD4⁺CXCR5⁺ is shown on the left and the statistical chart of healthy donors (27.72 ± 1.356%) and T2DM patients (33.88 ± 1.042%) is shown on the right and (b) correlation analysis for Tfh cells and T2DM characters including FPG, BMI, insulin, HbA1C, diabetes duration, and fasting plasma C-peptide.

Figure 2.

The frequency of Tim-3 on circulating Tfh cells was detected by flow cytometry: (a) scatter diagram for Tim-3 frequency on CXCR5⁺ Tfh cells gated by CD4⁺ (left); statistical chart of healthy donors (n = 20, 7.02 ± 0.773%) and T2DM patients (n = 30, 11.94 ± 1.270%) (right) and (b) correlation analysis for Tim-3 frequency on Tfh cells and T2DM characters including FPG, BMI, insulin, HbA1C, diabetes duration and fasting plasma C-peptide.

Figure 3.

Quantification of circulating Tfh cells and corresponding Tim-3 frequency by the stimulation with low and high concentration glucose: (a) the scatter diagram (left) and statistical chart (right) for Tfh cell abundance are shown and (b) the frequency of Tim-3 on circulating Tfh cells is displayed in the scatter diagram (left) and statistical chart (right).

In vitro experiment

The lymphocytes from 6 healthy donors were isolated by EZ-Sep™ lymphocyte separation (Dakewe, China). The cells were cultured in DMEM sugar-free medium and stimulated by high concentration (25 mmol/L) and low concentration (5 mmol/L) glucose in cell culture medium for 24 h. The abundance of Tfh (CD4⁺CXCR5⁺) and the frequency of Tim3 on cTfh cells were analyzed by flow cytometry.

Statistical analysis

Statistical analysis was performed using Prism GraphPad Software (version 6.0). Comparison between two groups was calculated by unpaired t test. In the correlation section, the Pearson correlation analysis was used. p < 0.05 was considered statistically significant.

Results

cTfh cells are more abundant in patients with T2DM than healthy donors

We first analyzed the abundance of cTfh cells from patients with T2DM and healthy donors. The cTfh cells were marked with CD4 and CXCR5. As shown in Figure 1(a), T2DM patients (33.88 ± 1.042%) displayed more cTfh cells than healthy donors (27.72 ± 1.356%; p < 0.001).

The relationship between cTfh and characteristics of T2DM

We next evaluated the correlation between Tfh cells and T2DM characteristics as shown in Table 1 (fasting plasma glucose (FPG); body mass index (BMI); insulin; HbA1C; diabetes duration; fasting plasma C-peptide). No significant correlation was found between cTfh cells and FPG, BMI, or insulin. A negative correlation was found between cTfh cells and HbA1C (Figure 1(b), r = −0.4424, p-value = 0.0392) and diabetes duration (Figure 1(b), r = −0.4020, p-value = 0.0339). HbA1C can provide insight into blood glucose control over recent months in patients with T2DM. A strong positive correlation was also found between cTfh cells and fasting plasma C-peptide (Figure 1(b), r = 0.6223, p-value = 0.0044).

The frequency of Tim-3 on cTfh cells and the relationship with T2DM

We analyzed the frequency Tim-3 on cTfh cells (CD4⁺CXCR5⁺) by flow cytometry. As shown in Figure 2(a), the cTfh cells from T2DM patients (11.94 ± 1.270%) expressed much more Tim-3 than those from healthy donors (7.02 ± 0.773%) (p-value < 0.01). However, no significant correlations between the frequency of Tim-3 on cTfh cells and T2DM characters in the correlation analysis (Figure 2(b)).

High glucose increases the abundance of Tfh cells in vitro

Since the fundamental characteristic of T2DM is hyperglycemia, we stimulated lymphocytes with low- and high-concentration glucose for 24 h in vitro and performed flow cytometry to detect the amount of cTfh cells and Tim-3 frequency. High-concentration glucose increased the amount of cTfh cells (Figure 3(a)); however, the frequency of Tim-3 on cTfh cells was not influenced by the concentration of glucose (Figure 3(b)).

Discussion

We examined the number and role of cTfh cells and associated Tim-3 frequency in patients with T2DM. Our results demonstrate an increase in the amount of cTfh cells in T2DM patients compared with healthy donors (Figure 1(a)). Tfh cells are a subset of CD4⁺ T cells that promote the B cell maturity.¹⁵ Recent studies have identified the role of chronic inflammation in the progression of T2DM.^33–35 B cells are responsible for the release of cytokines such as IL-6 and TNF-α in T2DM, which is closely related to chronic inflammation and insulin resistance.^36,37 Therefore, it appears that elevation of Tfh cells in T2DM may promote B cells to release pro-inflammatory cytokines and aggravate the progression of T2DM.

The correlation between T2DM characteristics and cTfh cells (Figure 1(b)) has been identified. The negative correlation between HbA1c and cTfh cells indicates that poor control of blood glucose levels decreases the amount of cTfh cells. However, the reason why the abundance of cTfh cells correlates with HbA1c but not FBG remains unclear. cTfh cell number is related to chronic inflammation, and we illustrated a clear relationship with T2DM. However, the negative correlation between diabetes duration and cTfh cells is associated with the body’s adaption to the long-term diabetes duration that reduced the amount of cTfh cells, although the detailed mechanisms need to be further explored. Fasting plasma C-peptide testing is more accurate to reflect the insulin released level by islet B cells and the body’s insulin resistance level than plasma insulin testing in T2DM patients, especially those who rely on insulin injections. Therefore, the positive correlation between plasma C-peptide level rather than insulin level and cTfh cells indicates that more cTfh cells leads to higher insulin resistance. In contrast to Wang et al.’s study, which showed a correlation between BMI of T2DM patients and the amount of cTfh cells,²¹ our results showed no significant correlation between the two parameters. This difference might be due to sample variation.

Our findings also indicate that the frequency of Tim-3 on cTfh cells is higher in patients with T2DM compared with healthy controls. Tim-3 is closely related to the immune tolerance.^23,38 Our previous studies indicated that the expression of Tim-3 on CD14⁺ cells is down-regulated in T2DM patients³⁹ due to high Tim-3 expression that promotes the transformation of macrophages to M2 with mainly anti-inflammatory effects.⁴⁰ In contrast with macrophages, we identified elevated frequency of Tim-3 on cTfh cells (Figure 2(a)). The body’s adaption to chronic inflammation and negative feedback regulation for the decline of Tim-3 expression on macrophages may illustrate this phenomenon. Interestingly, Kurose et al. found that expression of Gal-9 (galectin-9), the ligand of Tim-3, increased in the blood of patients with T2DM due to renal lesions.³¹ This is a novel research pathway especially in patients with diabetic nephropathy. We found no significant correlation between T2DM characteristics and Tim-3 frequency on cTfh cells (Figure 2(b)); therefore, the factors that are directly correlated with Tim-3 expression on cTfh cells in T2DM remain unclear.

We also showed that high glucose concentration could directly stimulate cTfh cell activation and increase the differentiation of CD4⁺ cells into Tfh cells (Figure 3(a)). Conversely, there is no direct relationship between the concentration of glucose and the frequency of Tim-3 on cTfh cells (Figure 3(b)). This indicates that it is the chronic inflammation and aberrant immune environment in T2DM that cause the change of Tim-3 expression rather than high glucose concentration. Importantly, further research is needed to explore the detailed mechanisms relating to what factors can directly impact Tim-3 expression in T2DM.

However, there are also some limitations of this study. Firstly, the sample size wasn’t calculated and justified by professional statistical software in this study; secondly, we just detected the frequency of Tim-3 on cTfh cells, the ligand of Tim-3 and the Tim-3 function was not identified; finally, limited by the volume of peripheral blood collection, we were unable to detect the downstream signaling pathways of Tim-3.

Conclusion

Our research provides a new perspective for the understanding of T2DM. Elevated cTfh cells and Tim-3 frequency may be a valuable avenue in order to explore the complex pathophysiological changes underlying T2DM.

Footnotes

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Our work was supported by the Key Research & Development Plan of Shandong Province (No. 2019GSF108013, 2019GSF108276, 2019GSF108242, 2019GSF108057), National Natural Science Foundation of China (81500339, 81600344, 81800775) and the opening foundation of Key Laboratory of Infection and Immunity of Shandong Province.

Ethical approval

Ethical approval for this study was obtained from The Ethics Committee of Qilu Hospital of Shandong University (2019027).

Informed consent

Written informed consent was obtained from all subjects before the study.

ORCID iD

Wenjiang Yan

References

International Diabetes Federation (2017) IDF diabetes Atlas. 8th ed. DiabetesAtlas. http://www.diabetesatlas.org/

Zheng

Ley

(2018) Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nature Reviews Endocrinology 14(2): 88–98.

Chatterjee

Khunti

Davies

(2017) Type 2 diabetes. The Lancet 389(10085): 2239–2251.

Baker

Hayden

Ghosh

(2011) NF-κB, inflammation, and metabolic disease. Cell Metabolism 13(1): 11–22.

Barnes

Yang

, et al. (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. Journal of Clinical Investigation 112(12): 1821–1830.

Fleischman

Shoelson

Bernier

, et al. (2008) Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 31(2): 289–294.

Lumeng

Deyoung

Bodzin

, et al. (2007) Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 56(1): 16–23.

Ilan

Maron

Tukpah

, et al. (2010) Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proceedings of the National Academy of Sciences USA 107(21): 9765–9770.

Berrou

Fougeray

Venot

, et al. (2013) Natural killer cell function, an important target for infection and tumor protection, is impaired in type 2 diabetes. PLoS One 8(4): e62418.

10.

Touch

Clement

Andre

(2017) T cell populations and functions are altered in human obesity and type 2 diabetes. Current Diabetes Reports 17(9): 81.

11.

Hotamisligil

Shargill

Spiegelman

(1993) Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science 259(5091): 87–91.

12.

Herder

Dalmas

Boni-Schnetzler

, et al. (2015) The IL-1 pathway in type 2 diabetes and cardiovascular complications. Trends in Endocrinology & Metabolism 26(10): 551–563.

13.

Akbari

Hassan-Zadeh

(2018) IL-6 signalling pathways and the development of type 2 diabetes. Inflammopharmacology 26(3): 685–698.

14.

Reardon

Lingaraju

Schoenfelt

, et al. (2018) Obesity and insulin resistance promote atherosclerosis through an IFNgamma-regulated macrophage protein network. Cell Reports 23(10): 3021–3030.

15.

(2016) T follicular helper cells in space-time. Nature Reviews Immunology 16(10): 612–625.

16.

Chtanova

Tangye

Newton

, et al. (2004) T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells. The Journal of Immunology 173(1): 68–78.

17.

Kenefeck

Wang

Kapadi

, et al. (2015) Follicular helper T cell signature in type 1 diabetes. The Journal of Clinical Investigation 125(1): 292–303.

18.

Zhang

Gong

Zhu

, et al. (2016) Augmentation of circulating follicular helper T cells and their impact on autoreactive B cells in myasthenia gravis. Journal of Immunology 197(7): 2610–2617.

19.

Kim

Lee

Diamond

(2018) Follicular helper T cells in systemic lupus erythematosus. Frontiers in Immunology 9: 1793.

20.

Liu

Yuan

, et al. (2018) Constitutive changes in circulating follicular helper T cells and their subsets in patients with graves’ disease. Journal of Immunology Research 2018: 8972572.

21.

Wang

Zhai

Chen

, et al. (2015) Dysregulation of circulating CD4+CXCR5+ T cells in type 2 diabetes mellitus. APMIS 123(2): 146–151.

22.

Zhang

Tai

, et al. (2016) Increased CD4+CXCR5+T follicular helper cells in diabetic nephropathy. Autoimmunity 49: 6405–6413.

23.

Sabatos

Chakravarti

Cha

, et al. (2003) Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nature Immunology 4: 1102–1110.

24.

Alderton

(2012) Immunology: TIM3 suppresses antitumour DCs. Nature Reviews Cancer 12(9): 584.

25.

Wang

Sun

Gao

, et al. (2017) Preoperative Tim3 expression on peripheral NK cells is correlated with pathologic TNM staging in colorectal cancer. Molecular Medicine Reports 15(6): 3810–3818.

26.

Monney

Sabatos

Gaglia

, et al. (2002) Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415(6871): 536–541.

27.

Liberal

Grant

Holder

, et al. (2012) The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9/tim-3 pathway. Hepatology 56(2): 677–686.

28.

Shi

, et al. (2012) Blockade of Tim-3 signaling restores the virus-specific CD8(+) T-cell response in patients with chronic hepatitis B. European Journal of Immunology 42(5): 1180–1191.

29.

Das

Zhu

Kuchroo

(2017) Tim-3 and its role in regulating anti-tumor immunity. Immunological Reviews 276(1): 97–111.

30.

de Mingo Pulido

Gardner

Hiebler

, et al. (2018) TIM-3 regulates CD103(+) dendritic cell function and response to chemotherapy in breast cancer. Cancer Cell 33(1): 60–74 e66.

31.

Kurose

Wada

Kanzaki

et al. (2013) Serum galectin-9 levels are elevated in the patients with type 2 diabetes and chronic kidney disease. BMC Nephrology 14: 23. DOI: 10.1186/1471-2369-14-23.

32.

Yang

Xie

, et al. (2019) Tim-3 aggravates podocyte injury in diabetic nephropathy by promoting macrophage activation via the NF-kappaB/TNF-alpha pathway. Molecular Metabolism 23: 24–36.

33.

Bremer

Jialal

(2013) Adipose tissue dysfunction in nascent metabolic syndrome. Journal of Obesity 2013: 393192.

34.

Wang

Yatsuya

Tamakoshi

, et al. (2013) Positive association between high-sensitivity C-reactive protein and incidence of type 2 diabetes mellitus in Japanese workers: 6-year follow-up. Diabetes/Metabolism Research and Reviews 29(5): 398–405.

35.

Belforte

Coluccio Leskow

Poskus

, et al. (2013) Toll-like receptor 4 D299G polymorphism in metabolic disorders: A meta-analysis. Molecular Biology Reports 40(4): 3015–3020.

36.

DeFuria

Belkina

Jagannathan-Bogdan

, et al. (2013) B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile. Proceedings of the National Academy of Sciences USA 110(13): 5133–5138.

37.

Jagannathan

McDonnell

Liang

, et al. (2010) Toll-like receptors regulate B cell cytokine production in patients with diabetes. Diabetologia 53(7): 1461–1471.

38.

Sánchez-Fueyo

Tian

Picarella

, et al. (2003) Tim-3 inhibits T helper type 1–mediated auto- and alloimmune responses and promotes immunological tolerance. Nature Immunology 4(11): 1093–1101.

39.

Yan

Sun

Wei

et al. (2016) T cell immunoglobulin and mucin domain-containing molecule 3 on CD14(+) monocytes serves as a novel biological marker for diabetes duration in type 2 diabetes mellitus. Journal of Diabetes Investigation 7(6): 867–873.

40.

Sun

Huang

, et al. (2018) miR-330-5p/Tim-3 axis regulates macrophage M2 polarization and insulin resistance in diabetes mice. Molecular Immunology 95: 107–113.